Hypovitaminosis-D and EBV: No interdependence between two MS risk factors in a healthy young UK autumn cohort

Multiple Sclerosis Journal

Volumn 20, Issue 6, 2014, Pages 751-753

  Ramien, Caren ^a   Pachnio, Annette ^b   Sisay, Sofia ^a   Begum, Jusnara ^b   Leese, Alison ^b   Disanto, Giulio ^c   Kuhle, Jens ^a   Giovannoni, Gavin ^a   Rickinson, Alan ^b   Ramagopalan, Sreeram V ^a   Moss, Paul ^b   Meier, Ute Christiane ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

environment; immunology; infection

Indexed keywords

CALCIFEDIOL; EPSTEIN BARR VIRUS ANTIGEN 1; HUMORAL ANTIBODY; EBV-ENCODED NUCLEAR ANTIGEN 1; EPSTEIN BARR VIRUS ANTIGEN; VIRUS ANTIBODY; VITAMIN D;

ARTICLE; EPSTEIN BARR VIRUS; EPSTEIN BARR VIRUS INFECTION; HUMAN; LIQUID CHROMATOGRAPHY; MULTIPLE SCLEROSIS; NORMAL HUMAN; POLYMERASE CHAIN REACTION; RISK FACTOR; TANDEM MASS SPECTROMETRY; UNITED KINGDOM; VIRUS LOAD; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; ADULT; COHORT ANALYSIS; IMMUNOLOGY; METABOLISM; SEASON; VIROLOGY; VITAMIN DEFICIENCY; YOUNG ADULT; CONTROLLED STUDY; HUMAN CELL; NEUROPATHOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; VIRUS TITRATION;

ADULT; ANTIBODIES, VIRAL; AVITAMINOSIS; COHORT STUDIES; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GREAT BRITAIN; HERPESVIRUS 4, HUMAN; HUMANS; MULTIPLE SCLEROSIS; RISK FACTORS; SEASONS; VITAMIN D; YOUNG ADULT;

EID: 84899078565     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458513509507     Document Type: Article

References (11)

1. Ramagopalan SV, Dobson R, Meier UC, et al. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010 ; 9: 727-739
2. Meier UC, Giovannoni G, Tzartos JS, et al. Translational Mini-Review Series on B cell subsets in disease. B cells in multiple sclerosis: drivers of disease pathogenesis and Trojan horse for Epstein-Barr virus entry to the central nervous system?. Clin Exp Immunol. 2012 ; 167: 1-6
3. Ascherio A, Munger KL, Lunemann JD. The initiation and prevention of multiple sclerosis. Nat Rev Neurol. 2012 ; 8: 602-612
4. Tzartos JS, Khan G, Vossenkamper A, et al. Association of innate immune activation with latent Epstein-Barr virus in active MS lesions. Neurology. 2012 ; 78: 15-23
5. Munger KL, Levin LI, Hollis BW, et al. Serum 25-Hydroxyvitamin D levels and risk of Multiple Sclerosis. JAMA. 2006 ; 296: 2832-2838
6. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metabol. 2011 ; 96: 1911-1930
7. Ramagopalan SV, Heger A, Berlanga AJ, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: associations with disease and evolution. Genome Res. 2010 ; 20: 1352-1360
8. Yenamandra SP, Hellman U, Kempkes B, et al. Epstein-Barr virus encoded EBNA-3 binds to vitamin D receptor and blocks activation of its target genes. Cell Mol Life Sci: CMLS. 2010 ; 67: 4249-4256
9. Gallagher A, Armstrong AA, MacKenzie J, et al. Detection of Epstein-Barr virus (EBV) genomes in the serum of patients with EBV-associated Hodgkin's disease. Int J Cancer. 1999 ; 84: 442-448
10. Disanto G, Handel AE, Damoiseaux J, et al. Vitamin D supplementation and antibodies against the Epstein-Barr virus in multiple sclerosis patients. Mult Scler. 2013 ;:
11. Laaksi I, Ruohola J-P, Tuohimaa P, et al. An association of serum vitamin D concentration < 40 nmol/L with acute respiratory tract infection in young Finnish men. Am J Clin Nutr. 2007 ; 86: 714-717